Boston Scientific drops plans to sell pain unit

Bloomberg has reported that Boston Scientific has abandoned its plans to auction off its neuromodulation business, which it had hoped to sell for up to $2 billion. Sources say companies interested in a deal were looking to pay $1 billion to $1.5 billion for the pain treatment division--much less that Boston Sci was asking. Article

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.